Clinical trial NCT06165172: Early Feasibility Study of the MyoRegulator® for Treatment of ALS
Official title: Early Feasibility Study of the MyoRegulator® for Treatment of ALS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Amyotrophic Lateral Sclerosis
Keywords: amyotrophic lateral sclerosis
neuromodulation
motor neuron hyperexcitability suppression
non-invasive
Lead sponsor: PathMaker Neurosystems Inc.
Sponsor class: INDUSTRY
Collaborators: name: Spaulding Rehabilitation Hospital
name: Sean M. Healey & AMG Center for ALS
name: Muscular Dystrophy Association
First posted: 2023-12-11
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This is a single-center, single-arm, open-label study aiming to assess the safety and feasibility of the MyoRegulator® device when used to treat individuals with amyotrophic lateral sclerosis (ALS). This study is the first use of the MyoRegulator® device to treat individuals with ALS. The main objective of this study is to confirm that individuals with ALS can tolerate the study treatment regimen without any evidence of serious adverse events related to the use of the device.

The MyoRegulator® device is a non-significant risk (NSR) investigational non-invasive neuromodulation device that uses multi-site direct current (multi-site DCS) stimulation. It has been used in two completed clinical trials evaluating its efficacy to treat post-stroke muscle spasticity and is currently being evaluated in a third trial in this post-stroke population.

Detailed description: Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that affects motor neurons in spinal cord and brain. ALS causes motor and cognitive function deficits and eventual death, typically within 2-5 years of diagnosis. There are at least 30,000 ALS patients in the United States and about 5,000 new diagnoses every year according to the Centers for Disease Control (CDC).

Recent research has established important links between ALS and motor neuron hyperexcitability and suggest that motor neuron hyperexcitability is found across different ALS variants.

The multi-site DCS MyoRegulator® treatment is a non-invasive approach to the suppression of motor neuron hyperexcitability based on multi-site direct current stimulation (DCS). Pre-clinical studies show that treatment using multi-site DCS effectively slows disease progression in transgenic mouse models of ALS. This is associated with improved motor function, preservation of motor neurons, and improved animal survival.

This clinical study is a non-significant risk (NSR) investigation using the non-invasive multi-site DCS MyoRegulator® to evaluate the feasibility and safety of treatment with MyoRegulator® in individuals with ALS. The primary endpoint is feasibility and safety. Feasibility will be evaluated by recording and assessing the proportion potential participants who are enrolled from the total number of participants screened for the study, the ease of delivering treatment, the tolerability of study participants to the treatment, and the compliance of study participants with the study schedule and evaluations. Safety will be evaluated by recording the frequency and duration of any adverse events reported by study participants or observed by physical examination during or following treatment and throughout the study duration.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* A clinical diagnosis of ALS as confirmed by medical history
* Willing to forgo botulinum toxin, phenol or alcohol injections, intrathecal baclofen, digitalis, and morphine for the study duration
* Willing to refrain from participation in any other clinical trial for the duration of this study
* Willing to forgo pregnancy for the duration of the study
* Willing and able to give informed consent or have informed consent provided for them by their legal guardian
* Cognitive function sufficient to understand the study and follow instructions (per interview with appropriate clinician)

Exclusion Criteria:

* Study participants who are on permanent assisted ventilation (PAV) defined as \>22h of noninvasive or invasive ventilation a day for \> 7 consecutive days.
* Implanted intrathecal pump
* Prior botulinum toxin injection(s) within 12 weeks of study enrollment
* Prior phenol or alcohol injections within 6 months of study enrollment
* Presence of potential risk factors for trans-spinal direct current stimulation:
* Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)
* Lack of sensory perception at the stimulation sites
* Presence of an electrically, magnetically, or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders
* Ferrous metal in the path of the current flow (jewelry must be removed during stimulation)
* Past history of epileptic seizures or unexplained spells of loss of consciousness during the previous 36 months
* Any medical condition that would prevent the participant from being able to participate in the clinical outcome measures
* Pregnant females, as determined by a pregnancy test at enrollment (in females of child-bearing potential)

Primary outcomes:
measure: Safety as measured by number of patients with any device-related serious adverse event
timeFrame: Up to 4 weeks following the last treatment
measure: Tolerability as measured by patient's ability to complete the treatments
timeFrame: Up to 4 weeks following the last treatment
Secondary outcomes:
measure: Improvement in Functionality
timeFrame: Up to 4 weeks following the last treatment
measure: Improvement in Activities of Daily Living
timeFrame: Up to 4 weeks following the last treatment
measure: Improvement in Quality of Life
timeFrame: Up to 4 weeks following the last treatment
Other outcomes:
Locations:
city: Charlestown
country: United States
facility: Spaulding Rehabilitation Hospital
state: Massachusetts
Study officials:
affiliation: Spaulding Rehabilitation Hospital
name: J. Leon Morales-Quezada, M.D, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: